CN101455658A - Use of salvianolic acid A and medicine composition thereof from Salia miliiorrhiza Bge. - Google Patents
Use of salvianolic acid A and medicine composition thereof from Salia miliiorrhiza Bge. Download PDFInfo
- Publication number
- CN101455658A CN101455658A CNA2007101792826A CN200710179282A CN101455658A CN 101455658 A CN101455658 A CN 101455658A CN A2007101792826 A CNA2007101792826 A CN A2007101792826A CN 200710179282 A CN200710179282 A CN 200710179282A CN 101455658 A CN101455658 A CN 101455658A
- Authority
- CN
- China
- Prior art keywords
- salvianolic acid
- arrhythmia
- group
- danshen root
- root salvianolic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention discloses salvianolic acid A and a novel use of pharmaceutical composition comprising salvianolic acid A. The invention is characterized by the application of salvianolic acid A in preparing the medicament for treating arrhythmia, and the application of pharmaceutical composition composed of salvianolic acid A, ginseng, ophiopogon root, cornus officinalis, quinidine, lignocaine, etc. in preparing the medicament for treating arrhythmia. The pharmaceutical and clinical researches show that the salvianolic acid A and pharmaceutical composition comprising salvianolic acid A have excellent treating function for arrhythmia.
Description
Technical field
The present invention relates to the field of Chinese medicines, relate to danshen root salvianolic acid A and a kind of new pharmaceutical usage that contains the danshen root salvianolic acid A pharmaceutical composition.
Arrhythmia of the present invention mainly is meant common cardiac arrhythmia in the clinical hospital.
Arrhythmia of the present invention refers to that rhythm of the heart origin position, cardiac frequency and the rhythm and pace of moving things and conduction of impulse etc. are arbitrary unusual.
Arrhythmia of the present invention mainly is meant: frequency, the rhythm and pace of moving things, origin position, conduction velocity or exciting order unusual that is meant cardiac impulse.By its occurring principle, divide into impulsion and form unusual and conduction of impulse unusual two big classes.Impulsion forms unusual: (one) sinus arrhythmia 1, sinus tachycardia; 2, sinus bradycardia; 3, arrhythmia; 4, sinus arrest; (2) 1. escape beat (room, atrioventricular junction, chamber property) of ectopic cardiac rhythm 1, passivity ectopic cardiac rhythm; 2. escape rhythm (room, atrioventricular junction, chamber property).2,1. premature beat of active ectopic rhythm (room, atrioventricular junction, chamber property); 2. paroxysmal tachycardia (room, atrioventricular junction, turning back property of chamber, chamber property); 3. atrial flutter, atrial fibrillation; 4. ventricular flutter, ventricular fibrillation.Conduction of impulse is unusual: 1, physiological is disturbed and atrioventricular dissociation.2,1. sinoatrial block of pathologic; 2. conduction block in the room; 3. atrioventricular block; 4. bundle branch or fascicular block (left and right bundle branch and left bundle branch fascicular block) or intraventricular block.3, the unusual preexcitation syndrome of pathway between chamber.The speed of heart rate when taking place according to arrhythmia can be divided into it tachyarrhythmia and bradyarrhythmia two big classes.
Background technology
Normal cardiac rhythm originates from sinuatrial node, 60 times～100 times/min of frequency (adult), and comparison rule, the sinuatrial node impulsion is through normal atrioventricular conduction system exciting atrium of order and ventricle, conduction time constant (being grown up 0.12～1.21 second); Impulsion is through the conduction time also constant (＜0.10 second) of bundle branch and branch and Purkinje fiber arrival ventricular muscles.Arrhythmia (cardiac arrhythmia) refers to rhythm of the heart origin position, cardiac frequency and the rhythm and pace of moving things and conduction of impulse etc., and each is unusual.Arrhythmia not only comprises the rhythm and pace of moving things but also comprise the unusual of frequency.Arrhythmia can be by occurring principle, the speed of heart rate during arrhythmia, and the circulatory disturbance order of severity and prognosis classification during arrhythmia.Press occurring principle, arrhythmia is divided into that unusual, conduction abnormalities takes place in impulsion and impulsion takes place with the conduction associating unusual, in addition, the mechanism that some tachy-arrhythmia initial sum continues may be different, as the ventricular premature contraction that causes by unusual self-disciplining, can form by foldback mechanism and continue the type ventricular tachycardia.The speed of heart rate during by arrhythmia, arrhythmia can be divided into rapidity and bradyarrhythmia.The circulatory disturbance order of severity and prognosis are divided into mortality, potential mortality and optimum three classes with arrhythmia when proposing by arrhythmia in recent years.
Treatment and prevention outbreak when ARR treatment should comprise outbreak.Except that etiological treatment, still can be divided into Drug therapy and non-drug therapy two aspects.Etiological treatment comprises and corrects the heart pathological change, adjusts unusual Pathophysiology function (dynamically narrow as arteria coronaria, pumping function is complete, autonomic nervous tension change etc.), and removes other inducement (as electrolyte disturbance, adverse drug side effect etc.) that causes arrhythmia episode.Drug therapy is slow, arrhythmia generally select for use strengthen myocardium self-disciplining and (or) medicine that quickens conduction, suppress medicine (atropine) or basifier (mole sodium lactate or sodium bicarbonate) as sympathomimetic (isoproterenol etc.), vagus nerve.The treatment tachy-arrhythmia is then selected for use and is slowed down conduction and prolong the medicine of refractory stage, as vagal excitation agent (neostigmine, digitalis preparation), sympathomimetic indirect excitation vagus nerve (methoxamedrine, phenylephrine) or antiarrhythmic drug.The antiarrhythmic drug of clinical practice at present is existing more than 50 kinds, often by be used for classify (the Vaugham Williams method) of medicine to the myocardial cell action potential.I class medicine suppresses 0 phase depolarization, once is called as the film inhibitor, and is strong and weak and to the Different Effects of refractory stage and conduction velocity by the inhibition degree, is further divided into I a, I b and I c subclass, respectively with quinidine, lignocaine and encainide as representative drugs.The II class is an adrenergic; III class over reach current potential time limit and refractory stage are representative drugs with the amiodarone; The IV class is a flow blocker in the calcium, is representative drugs with the verapamil.Antiarrhythmic drug is taken the adverse side effect that all has in various degree for a long time, serious caused ventricular arrhythmia or heart block and fatal.Thereby the appropriate to the occasion strict indication of grasping of clinical practice, and the effect of familiar several antiarrhythmic drugs commonly used, comprise half-life, absorption, decomposition, drainage, active metabolite, dosage and side effect; Non-drug therapy comprises the mechanical means excited vagus, cardiac pacemaker, and electrical conversion, electric defibrillation, electricity melts, radio-frequency (RF) ablation and freezing or laser ablation and operative treatment, but the expense of non-drug therapy is very high, and a lot of patients can't accept.
In sum, research and develop a kind of medicine new, that side effect is little, the treatment arrhythmia is a lot of medical workers, clinician and the common hope of patient.
Salvianolic acid A [salvianolic acid A] is one of effective component in red sage, Du Guanhua [preclinical medicine and clinical, 2000,20 (5): 10～14] etc. the people has carried out big quantity research to the activity of salvianolic acid A, find that salvianolic acid A has good therapeutical effect to cardiovascular and cerebrovascular disease, but up to now, any bibliographical information is not arranged, danshen root salvianolic acid A or contain danshen root salvianolic acid A have the treatment ARR effect.
Summary of the invention
For these reasons, our scientific research personnel is in pharmacological evaluation, and the pharmaceutical composition of finding danshen root salvianolic acid A unexpectedly or containing danshen root salvianolic acid A has the ARR effect of treatment; Checking by experiment, danshen root salvianolic acid A or the pharmaceutical composition that contains danshen root salvianolic acid A have excellent effect, the little characteristics of side effect aspect the treatment arrhythmia.
The present invention is achieved through the following technical solutions.
The application of danshen root salvianolic acid A in preparation treatment antiarrhythmic medicament.
Contain the application of pharmaceutical composition in preparation treatment antiarrhythmic medicament of danshen root salvianolic acid A.
Arrhythmia of the present invention mainly is meant common cardiac arrhythmia in the clinical hospital.
Arrhythmia of the present invention refers to that rhythm of the heart origin position, cardiac frequency and the rhythm and pace of moving things and conduction of impulse etc. are arbitrary unusual.
Arrhythmia of the present invention mainly is meant: frequency, the rhythm and pace of moving things, origin position, conduction velocity or exciting order unusual that is meant cardiac impulse.By its occurring principle, divide into impulsion and form unusual and conduction of impulse unusual two big classes.Impulsion forms unusual: (one) sinus arrhythmia 1, sinus tachycardia; 2, sinus bradycardia; 3, arrhythmia; 4, sinus arrest; (2) 1. escape beat (room, atrioventricular junction, chamber property) of ectopic cardiac rhythm 1, passivity ectopic cardiac rhythm; 2. escape rhythm (room, atrioventricular junction, chamber property).2,1. premature beat of active ectopic rhythm (room, atrioventricular junction, chamber property); 2. paroxysmal tachycardia (room, atrioventricular junction, turning back property of chamber, chamber property); 3. atrial flutter, atrial fibrillation; 4. ventricular flutter, ventricular fibrillation.Conduction of impulse is unusual: 1, physiological is disturbed and atrioventricular dissociation.2,1. sinoatrial block of pathologic; 2. conduction block in the room; 3. atrioventricular block; 4. bundle branch or fascicular block (left and right bundle branch and left bundle branch fascicular block) or intraventricular block.3, the unusual preexcitation syndrome of pathway between chamber.The speed of heart rate when taking place according to arrhythmia can be divided into it tachyarrhythmia and bradyarrhythmia two big classes.
The pharmaceutical composition that contains danshen root salvianolic acid A of the present invention, comprise with the danshen root salvianolic acid A being the prescription of monarch drug or ministerial drug, wherein with the Radix Ginseng that comprises of danshen root salvianolic acid A compatibility, Radix Ophiopogonis, Fructus Corni, Semen Ziziphi Spinosae, Herba Taxilli, Radix Paeoniae Rubra, Eupolyphaga Seu Steleophaga, Radix Et Rhizoma Nardostachyos, Rhizoma Coptidis, Fructus Schisandrae Chinensis, Os Draconis, Radix Scutellariae, Radix Isatidis, Folium Isatidis, Radix Codonopsis, Poria, the Rhizoma Atractylodis Macrocephalae, river a kind of reed mentioned in ancient books, the Radix Astragali, Semen Platycladi, Flos Lonicerae, Radix Bupleuri, Radix Ophiopogonis, Radix Notoginseng, Radix Aconiti Lateralis Preparata, Ramulus Cinnamomi, Herba Asari, Herba Ephedrae, Herba Epimedii, Radix Glycyrrhizae, Radix Sophorae Flavescentis, Fructus Crataegi, in the Chinese medicines such as Rhizoma Polygonati in effective ingredient or the effective site one or more.
The pharmaceutical composition that contains danshen root salvianolic acid A of the present invention comprises danshen root salvianolic acid A and quinidine, the procainamide disopyramide, lignocaine, phenytoin, encainide, Propranolol, amiodarone, sotalol, verapamil, bepridil, diltiazem, isoproterenol, the yellow alkali of bed, epinephrine, the atropic category, thyroxin, adrenocortical hormone, the mole sodium lactate, nicotiamide, ajmaline, pirmenol, aprindine, lignocaine, phenytoin, mexiletine, tocainide, flecainide, lorcainide, Propafenone, in the anti-arrhythmics such as aetmozine one or more.
The pharmaceutical composition that contains danshen root salvianolic acid A of the present invention comprises in danshen root salvianolic acid A and above-mentioned Chinese medicine, the anti-arrhythmic one or more.
The pharmaceutical composition that contains danshen root salvianolic acid A of the present invention is not limited to the pharmaceutical composition of the drug regimen of above-mentioned record.
Said medicine or preparation of pharmaceutical compositions become the pharmaceutical preparation of pharmacy acceptable, are used for treating arrhythmia.
One, pharmacological evaluation
1, to the influence of rat ventricular
Experimental technique: rat with 2% pentobarbital sodium intraperitoneal anesthesia, is opened breast and cores, the residual blood of emptying heart, aortic cannulation places Langendorff isolated heart perfusion device, implements acyclic retrograde perfusion.Perfusion K-H liquid, its composition (mmol/L): sodium chloride 119.0, potassium chloride 4.0, KH
2PO
41.2, MgSO
41.2, NaHCO
325.0, CaCl
22.5, glucose 11.0, pH7.4 ± 0.5.Liquid is used 95%O all the time
2+ 5%CO
2The mist trim, temperature keeps 37 ℃.
With rat (male and female are not limit) random packet (10 every group).(1) normal control group: with K-H liquid continous perfusion 90min; (2) ischemia/reperfusion group (I/R): heart pours into 10min → stop in advance and irritates (spacious putting) 40min → irritate again 40min; (3) danshen root salvianolic acid A protection group: the filling phase adds danshen root salvianolic acid A in advance, and making its final concentration is 10 μ mol/L, and additive method is with (2); (5) contain danshen root salvianolic acid A pharmaceutical composition protection group: the filling phase adds and contains the danshen root salvianolic acid A pharmaceutical composition in advance, and making its final concentration is 10 μ mol/L, and additive method is with (2); (5) WENXIN KELI protection group: the filling phase adds WENXIN KELI in advance, and making its final concentration is 10 μ mol/L, and additive method is with (2);
Observation item and method: electrocardiogram: two electrodes are inserted in apex (+) and the variation of aortic root (-) monitoring electrocardiogram respectively, primary part observation ventricular tachycardia (ventricular tachycardia, VT), chamber property Fibrillation (ventricular fibrillation, VF), chamber property ectopic rhythm (ven-tricular ectopic beats, VEBs) and atrioventricular block (atrialventricularblock, incidence rate AVB) and arrhythmia persistent period.Cardiac function: after heart placed Langendorff isolated heart perfusion device, implement acyclic retrograde perfusion, go mechanics and the hematodinamics index of left chamber intubate again through pressure transducer input 8-SP type polygraph thought-read rate and cardiac muscle: left indoor pressure peak value (LVSP), left ventricular end diastolic presssure (LVDEP), the maximum rate of change of left indoor pressure (± dp/dt).Homogenate enzymatic determination: after cardiac perfusion finishes, cardiac muscle is ground with Potter-Elvehjem Tissue Grinders and make 10% tissue homogenate, behind the centrifugal 10min of 3000r/min-1, get supernatant, detect indexs such as SOD, MDA, LDH, CPK respectively.MDA measures the TBA method that adopts; SOD measures and adopts hydroxylamine assay; LDH measures and adopts colorimetry; CPK measures and adopts NAC activation method (enzyme coupling method); Determining the protein quantity adopts the Coomassie brilliant blue method.Step requires to carry out in strict accordance with description.Myocardial ultrastructure is observed: each group is got left chamber cardiac muscle, be cut into 2mm * 2 mm * 2 mm sizes, fixing before 2.5% glutaraldehyde, fixing behind 1% osmic acid, acetone dewaters step by step, paraffin embedding, ultrathin section, 1% uranium acetate and lead citrate double staining, H-600A type transmission electron microscope (HIT) is observed.
Experimental result:
(1) rat is poured into again the influence of arrhythmia: compare with the I/R group, the danshen root salvianolic acid A group and contain danshen root salvianolic acid A pharmaceutical composition group again the incidence of arrhythmia of flush phase significantly reduce, persistent period obviously shortens (P＜0.01), and experimental result sees Table 1.
The influence of table 1 pair rat ventricular
Annotate: compare with the ischemia group
*P＜0.01; Compare #P＜0.05 with the WENXIN KELI group.
(2) to the influence of cardiac function
With I/R group and normal group relatively, LVSP and ± dp/dtmax reduces, LVDEP raises (P＜0.05 or P＜0.01); And danshen root salvianolic acid A group and contain danshen root salvianolic acid A pharmaceutical composition group and I/R group relatively, LVSP and ± dp/dtmax rising, LVDEP reduce (P＜0.05 or P＜0.01), see Table 2.
The influence of table 2 pair cardiac functional parameter
Annotate: compare with the ischemia group
*P＜0.01,
*P＜0.05; Compare #P＜0.05 with the WENXIN KELI group.
(3) to the influence of tissue homogenate SOD, LDH, CPK activity and MDA content
Again after the perfusion, LDH and CPK activity are starkly lower than the normal control group in the tissue homogenate, MDA content is apparently higher than the normal control group, the SOD activity is lower than the normal control group, danshen root salvianolic acid A group and contain the minimizing that spills that danshen root salvianolic acid A pharmaceutical composition group then makes LDH and CPK, SOD is active to be increased, and MDA content reduces, and sees Table 3.
The influence of table 3 couple tissue homogenate SOD, LDH, CPK activity and MDA content
Annotate: compare with the ischemia group
*P＜0.01,
*P＜0.05; Compare #P＜0.05 with the WENXIN KELI group.
(4) to myocardial ultrastructure effects
Electron microscope showed, the normal group myocardial ultrastructure is normal: the nuclear membrane structure is clear, and structure of mitochondria is intact, and it is clear that muscle segment respectively is with; The damage of I/R group cellularity is heavier: myocardial cell structure disturbance, muscle corpuscle pyknosis, chromatin margination, myofilament dissolving, mitochondrial crista arrangement disorder; Danshen root salvianolic acid A group and contain danshen root salvianolic acid A pharmaceutical composition group: myocardial cell two-layer core membrane structure is clear, and nuclear Zhou Daliang mitochondrion and muscle segment structure are intact;
2, calcium chloride is brought out the influence of rat ventricular
Experimental technique: the Wistar rat is divided into group at random: the normal saline matched group, WENXIN KELI group, danshen root salvianolic acid A group, contain danshen root salvianolic acid A pharmaceutical composition group.20% urethane is behind intraperitoneal injection of anesthesia (1.2mg/kg), and dorsal position is fixed, and it is subcutaneous that needle electrode inserts animal foot, record standard limbs II lead electrocardiogram.If electrocardiogram has ischemia or other unusual performance, then from this experiment, reject.The tail vein is after slowly injection is subjected to the reagent thing or waits capacity normal saline 10min, in 10s through intact 2% calcium chloride (140mg/kg) of tail intravenous injection, arrhythmia time of occurrence, persistent period, incidence of arrhythmia and mortality rate after the observation administration.
Experimental result: tail vein injection 2% calcium chloride can bring out experimental rat 100% arrhythmia takes place, and mortality rate is up to 100%; With the normal saline group relatively, the danshen root salvianolic acid A group, contain danshen root salvianolic acid A pharmaceutical composition group and can obviously postpone ARR generation (P＜0.01), shorten the ARR persistent period (P＜0.01), can reduce incidence of arrhythmia and mortality rate.Experimental result sees Table 4:
Table 4 pair calcium chloride brings out the influence of rat ventricular
Annotate: compare with normal group
*P＜0.01,
*P＜0.05; Compare ##P＜0.01 with the WENXIN KELI group.
3, aconitine is brought out the influence of rat ventricular
Experimental technique: the Wistar rat is divided into group at random: the normal saline matched group, WENXIN KELI group, danshen root salvianolic acid A group, contain danshen root salvianolic acid A pharmaceutical composition group.Anesthesia, method fixing and recording ecg are the same.The tail vein slowly injection be subjected to the reagent thing or etc. behind the capacity normal saline 10min, use constant flow pump through the tail venous perfusion with 10 μ g/ (1ml/min) the 10mg/L aconitine, the time of ventricular premature contraction (VE), ventricular tachycardia (VT), ventricular fibrillation (VF) appears in the record rat, calculate the consumption that VE, VT, the required aconitine of VF take place each treated animal, and compare between organizing.
Experimental result: the danshen root salvianolic acid A group, contain danshen root salvianolic acid A pharmaceutical composition group and all can obviously improve the consumption that aconitine brings out rat VE, VT, VF, with normal saline group comparing difference significantly (P＜0.01).Experimental result sees Table 5.
Table 5 pair aconitine brings out the influence of rat ventricular
Annotate: compare with normal group
*P＜0.01,
*P＜0.05; Compare #P＜0.05 with the WENXIN KELI group.
Experiment conclusion: show that by above-mentioned pharmacological evaluation danshen root salvianolic acid A has good therapeutical effect with the pharmaceutical composition that contains danshen root salvianolic acid A to arrhythmia, proves absolutely that the present invention has scientific meaning.
Two, embodiment
Embodiment 1
Danshen root salvianolic acid A is used for treating arrhythmia.
Embodiment 2
With the danshen root salvianolic acid A is raw material, according to the conventional requirement of pharmaceutics, is prepared into the pharmaceutical preparation of pharmacy acceptable, is used for treating arrhythmia.
Embodiment 3
With the danshen root salvianolic acid A is the prescription of monarch drug or ministerial drug, wherein form pharmaceutical compositions, be used for treating arrhythmia with in effective ingredient in the Chinese medicines such as Radix Ginseng, Radix Ophiopogonis, Fructus Corni, Semen Ziziphi Spinosae, Herba Taxilli, Radix Paeoniae Rubra, Eupolyphaga Seu Steleophaga, Radix Et Rhizoma Nardostachyos, Rhizoma Coptidis, Fructus Schisandrae Chinensis, Os Draconis, Radix Scutellariae, Radix Isatidis, Folium Isatidis, Radix Codonopsis, Poria, the Rhizoma Atractylodis Macrocephalae, river a kind of reed mentioned in ancient books, the Radix Astragali, Semen Platycladi, Flos Lonicerae, Radix Bupleuri, Radix Ophiopogonis, Radix Notoginseng, Radix Aconiti Lateralis Preparata, Ramulus Cinnamomi, Herba Asari, Herba Ephedrae, Herba Epimedii, Radix Glycyrrhizae, Radix Sophorae Flavescentis, Fructus Crataegi, Rhizoma Polygonati or the effective site one or more of comprising of danshen root salvianolic acid A compatibility.
Perhaps above-mentioned is raw material with the aforementioned pharmaceutical compositions, according to the conventional requirement of pharmaceutics, is prepared into pharmaceutically acceptable pharmaceutical preparation, is used for treating arrhythmia.
Embodiment 4
Danshen root salvianolic acid A and quinidine, the procainamide disopyramide, lignocaine, phenytoin, encainide, Propranolol, amiodarone, sotalol, verapamil, bepridil, diltiazem, isoproterenol, the yellow alkali of bed, epinephrine, the atropic category, thyroxin, adrenocortical hormone, the mole sodium lactate, nicotiamide, ajmaline, pirmenol, aprindine, lignocaine, phenytoin, mexiletine, tocainide, flecainide, lorcainide, Propafenone, the pharmaceutical composition of one or more compositions in the anti-arrhythmics such as aetmozine is used for treating arrhythmia.
Perhaps above-mentioned is raw material with the aforementioned pharmaceutical compositions, according to the conventional requirement of pharmaceutics, is prepared into pharmaceutically acceptable pharmaceutical preparation, is used for treating arrhythmia.
Embodiment 5
With in the medicine of embodiment 3 and 4 one or more, form pharmaceutical composition with danshen root salvianolic acid A, be used for treating arrhythmia.
Perhaps above-mentioned is raw material with the aforementioned pharmaceutical compositions, according to the conventional requirement of pharmaceutics, is prepared into pharmaceutically acceptable pharmaceutical preparation, is used for treating arrhythmia.
Annotate: the present invention's concrete technical scheme required for protection is not limited to the concrete combination of the expressed technical scheme of the foregoing description.
Annotate: arrhythmia of the present invention mainly is meant common cardiac arrhythmia in the clinical hospital.
Arrhythmia of the present invention refers to that rhythm of the heart origin position, cardiac frequency and the rhythm and pace of moving things and conduction of impulse etc. are arbitrary unusual.
Arrhythmia of the present invention mainly is meant: frequency, the rhythm and pace of moving things, origin position, conduction velocity or exciting order unusual that is meant cardiac impulse.By its occurring principle, divide into impulsion and form unusual and conduction of impulse unusual two big classes.Impulsion forms unusual: (one) sinus arrhythmia 1, sinus tachycardia; 2, sinus bradycardia; 3, arrhythmia; 4, sinus arrest; (2) 1. escape beat (room, atrioventricular junction, chamber property) of ectopic cardiac rhythm 1, passivity ectopic cardiac rhythm; 2. escape rhythm (room, atrioventricular junction, chamber property).2,1. premature beat of active ectopic rhythm (room, atrioventricular junction, chamber property); 2. paroxysmal tachycardia (room, atrioventricular junction, turning back property of chamber, chamber property); 3. atrial flutter, atrial fibrillation; 4. ventricular flutter, ventricular fibrillation.Conduction of impulse is unusual: 1, physiological is disturbed and atrioventricular dissociation.2,1. sinoatrial block of pathologic; 2. conduction block in the room; 3. atrioventricular block; 4. bundle branch or fascicular block (left and right bundle branch and left bundle branch fascicular block) or intraventricular block.3, the unusual preexcitation syndrome of pathway between chamber.The speed of heart rate when taking place according to arrhythmia can be divided into it tachyarrhythmia and bradyarrhythmia two big classes.
Claims (2)
1, the application of danshen root salvianolic acid A in preparation treatment antiarrhythmic medicament.
2, contain the application of pharmaceutical composition in preparation treatment antiarrhythmic medicament of danshen root salvianolic acid A.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101792826A CN101455658A (en) | 2007-12-12 | 2007-12-12 | Use of salvianolic acid A and medicine composition thereof from Salia miliiorrhiza Bge. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101792826A CN101455658A (en) | 2007-12-12 | 2007-12-12 | Use of salvianolic acid A and medicine composition thereof from Salia miliiorrhiza Bge. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101455658A true CN101455658A (en) | 2009-06-17 |
Family
ID=40766956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101792826A Pending CN101455658A (en) | 2007-12-12 | 2007-12-12 | Use of salvianolic acid A and medicine composition thereof from Salia miliiorrhiza Bge. |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101455658A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107432910A (en) * | 2016-12-07 | 2017-12-05 | 徐中平 | A kind of Chinese medicine preparation for treating arrhythmia cordis and preparation method thereof |
| CN115998814A (en) * | 2023-02-03 | 2023-04-25 | 四川新益峰生物制药有限公司 | Compound tilmicosin injection and preparation method thereof |
-
2007
- 2007-12-12 CN CNA2007101792826A patent/CN101455658A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107432910A (en) * | 2016-12-07 | 2017-12-05 | 徐中平 | A kind of Chinese medicine preparation for treating arrhythmia cordis and preparation method thereof |
| CN115998814A (en) * | 2023-02-03 | 2023-04-25 | 四川新益峰生物制药有限公司 | Compound tilmicosin injection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104666951A (en) | Traditional Chinese medicine composition for treating parturient paresis puerperal fever | |
| CN101011522A (en) | Chinese medicinal preparation for treating heart disease | |
| CN106138117A (en) | Ganoderma spore oil application in preparing prevention and cure of cardiovascular disease medicine | |
| CN102302552A (en) | Capsules for treating arrhythmia and preparation method thereof | |
| CN105412410A (en) | Traditional Chinese medicine preparation for preventing and treating radiographic contrast nephropathy | |
| CN101422562A (en) | Medicine for treating premature beat and atrial fibrillation | |
| CN101455658A (en) | Use of salvianolic acid A and medicine composition thereof from Salia miliiorrhiza Bge. | |
| CN103385995B (en) | Traditional Chinese medicine compound for treating arrhythmia and preparation method thereof | |
| US11160841B2 (en) | Method of treating a disease associated with potassium ion channel | |
| CN102908513A (en) | Application of traditional Chinese medicine composition in medicine for treating arrhythmia | |
| CN104740054B (en) | A kind of pharmaceutical composition for preventing and treating myocardial ischemia and its production and use | |
| CN101843763B (en) | Traditional Chinese medicine capable of treating complicated symptom of diabetes and stagnant heat and application thereof | |
| CN101342207A (en) | Chinese medicinal composition for treating coronary disease, stenocardia, arrhythmia, hyperlipemia and preparation method thereof | |
| CN104984268A (en) | Traditional Chinese medicine composition treating cerebral thrombosis and preparing method of traditional Chinese medicine composition | |
| CN109568481A (en) | A kind of Chinese prescription preparation for treating coronary heart disease | |
| CN104547522B (en) | A kind of Chinese medicine composition for treating arrhythmia cordis and its application | |
| CN101653547B (en) | Application of Chinese medicinal composition in preparation of medicament for preventing arrhythmia | |
| CN100348223C (en) | Medicine for treating ischemic cerebral disease and its prepn | |
| CN102861231A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating ventricular remodeling after myocardial infarction | |
| CN102309675B (en) | Application of Chinese medicine composition in preparing medicines for treating sick sinus syndrome | |
| CN104107219A (en) | Aerosol for treating coronary heart disease and angina pectoris and preparation process of aerosol | |
| CN105456684A (en) | Traditional Chinese medicine composition for Qi-Yin deficiency type atrial fibrillation and preparation method thereof | |
| CN102309674B (en) | Use of traditional Chinese drug composition in preparing drug for treating atrioventricular block | |
| CN103800482A (en) | Pharmaceutical composition for treating myocardial ischemia, and preparation method and application thereof | |
| CN102614411B (en) | Chinese medicinal preparation for treating coronary heart disease angina pectoris and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20090617 |